AbbVie Inc. (ABBV) Quarterly Revenue
The quarterly revenue for AbbVie Inc. (ABBV) is $15.00B with a period-over-period change of (9.72%). Quarterly revenue is the total sales generated during the latest fiscal quarter.
ABBV Quarterly Revenue Chart
Quarterly Revenue History
| Date | Quarterly Revenue | % Change |
|---|---|---|
| Q1 2026 | $15.00B | (9.72%) |
| Q4 2025 | $16.62B | +5.34% |
| Q3 2025 | $15.78B | +2.29% |
| Q2 2025 | $15.42B | +15.59% |
| Q1 2025 | $13.34B | (11.65%) |
| Q4 2024 | $15.10B | +4.44% |
| Q3 2024 | $14.46B | (0.01%) |
| Q2 2024 | $14.46B | +17.48% |
| Q1 2024 | $12.31B | (13.92%) |
| Q4 2023 | $14.30B | +2.69% |
| Q3 2023 | $13.93B | +0.45% |
| Q2 2023 | $13.87B | +13.42% |
| Q1 2023 | $12.22B | (19.15%) |
| Q4 2022 | $15.12B | +2.09% |
| Q3 2022 | $14.81B | +1.57% |
| Q2 2022 | $14.58B | +7.72% |
| Q1 2022 | $13.54B | (9.06%) |
| Q4 2021 | $14.89B | +3.79% |
| Q3 2021 | $14.34B | +2.74% |
| Q2 2021 | $13.96B | +7.29% |
| Q1 2021 | $13.01B | (6.12%) |
| Q4 2020 | $13.86B | +7.41% |
| Q3 2020 | $12.90B | +23.76% |
| Q2 2020 | $10.43B | +20.95% |
| Q1 2020 | $8.62B | (0.98%) |
| Q4 2019 | $8.70B | +2.65% |
| Q3 2019 | $8.48B | +2.71% |
| Q2 2019 | $8.26B | +5.45% |
| Q1 2019 | $7.83B | (5.74%) |
| Q4 2018 | $8.30B | +0.84% |
| Q3 2018 | $8.24B | (0.51%) |
| Q2 2018 | $8.28B | +4.34% |
| Q1 2018 | $7.93B | +2.52% |
| Q4 2017 | $7.74B | +10.64% |
| Q3 2017 | $7.00B | +0.73% |
| Q2 2017 | $6.94B | +6.21% |
| Q1 2017 | $6.54B | (3.80%) |
| Q4 2016 | $6.80B | +5.66% |
| Q3 2016 | $6.43B | (0.31%) |
| Q2 2016 | $6.45B | +8.29% |
| Q1 2016 | $5.96B | (6.91%) |
| Q4 2015 | $6.40B | +7.67% |
| Q3 2015 | $5.94B | +8.57% |
| Q2 2015 | $5.47B | +8.63% |
| Q1 2015 | $5.04B | (7.56%) |
| Q4 2014 | $5.45B | +8.63% |
| Q3 2014 | $5.02B | +1.89% |
| Q2 2014 | $4.93B | +7.96% |
| Q1 2014 | $4.56B | (10.72%) |
| Q4 2013 | $5.11B | +9.73% |
| Q3 2013 | $4.66B | (0.72%) |
| Q2 2013 | $4.69B | +8.39% |
| Q1 2013 | $4.33B | (16.84%) |
| Q4 2012 | $5.21B | +15.48% |
| Q3 2012 | $4.51B | +0.33% |
| Q2 2012 | $4.49B | +7.67% |
| Q1 2012 | $4.17B | (14.21%) |
| Q4 2011 | $4.86B | +10.33% |
| Q3 2011 | $4.41B | +3.14% |
| Q2 2011 | $4.27B | +9.69% |
| Q1 2011 | $3.90B | - |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael